Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keymed Biosciences, Inc. (HK:2162)
:2162
Holding HK:2162?
Track your performance easily
2162 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$26.60 - HK$47.50
Previous CloseN/A
Volume918.50K
Average Volume (3M)1.91M
Market Cap
HK$7.38B
Enterprise ValueHK$6.84B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Apr 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding279,735,570
10 Day Avg. Volume1,239,954
30 Day Avg. Volume1,910,979
Standard Deviation0.18
R-Squared0.06
Alpha0.00102
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)139.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$60.47Price Target Upside106.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Keymed Biosciences, Inc. News
PremiumCompany Announcements
Keymed Biosciences Secures Licensing Deal for CM313PremiumCompany Announcements
Keymed Biosciences Gains NMPA Approval for Stapokibart
PremiumCompany Announcements
Keymed Biosciences Relocates Hong Kong Headquarters
PremiumCompany Announcements
Keymed Biosciences’ CM336 Shows Promise in Myeloma Study
PremiumCompany Announcements
Keymed Biosciences Expands Global Reach with CM336 DealPremiumCompany Announcements
Keymed Biosciences’ Stapokibart Wins Approval in China
PremiumCompany Announcements
Keymed Biosciences Faces Steep Revenue DeclinePremiumCompany Announcements
Keymed Biosciences Schedules Crucial Financial MeetingOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.28% Mutual Funds
― Other Institutional Investors
95.15% Public Companies and
Individual Investors
2162 FAQ
What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$26.60 and its highest was HK$47.50 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$7.38B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s upcoming earnings report date is Apr 01, 2025 which is in 72 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Aug 27, 2024. The company reported -HK$1.372 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$1.372.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 279,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of -HK$1.372 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.313%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
---
Keymed Biosciences, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$60.47 (106.38% Upside)
HK$60.47 (106.38% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.81%
12-Months-Change
Fundamentals
Return on Equity
-24.84%
Trailing 12-Months
Asset Growth
-6.82%
Trailing 12-Months
Company Description
Keymed Biosciences, Inc.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.
---
2162 Stock 12 Month Forecast
Average Price Target
HK$60.47
▲(106.38% Upside)
Technical Analysis
Akeso, Inc.
―
CanSino Biologics, Inc. Class H
―
Times Neighborhood Holdings Ltd.
―
Everest Medicines Ltd.
―
Petro-king Oilfield Services Ltd.
―
Best Analysts Covering 2162
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-6.10%
reiterated a buy rating 21 days ago
Copying Wangbin Zhou's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -6.10% per trade.
---